These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35393224)

  • 1. Correlation of EGFR mutation subtypes and survival in surgically treated brain metastasis from non-small-cell lung cancer.
    Perng PS; Hsu HP; Lee PH; Huang CC; Lin CC; Lee JS
    Asian J Surg; 2023 Jan; 46(1):269-276. PubMed ID: 35393224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases.
    Wang J; Liu Z; Pang Q; Zhang T; Chen X; Er P; Wang Y; Wang P; Wang J
    BMC Cancer; 2020 Sep; 20(1):837. PubMed ID: 32883221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC.
    Lin CY; Chang CC; Su PL; Lin CC; Tseng YL; Su WC; Yen YT
    Medicine (Baltimore); 2019 Aug; 98(33):e16766. PubMed ID: 31415376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy.
    Shah PP; Franke JL; Medikonda R; Jackson CM; Srivastava S; Choi J; Forde PM; Brahmer JR; Ettinger DS; Feliciano JL; Levy BP; Marrone KA; Naidoo J; Redmond KJ; Kleinberg LR; Lim M
    J Neurosurg; 2022 Jan; 136(1):56-66. PubMed ID: 34087798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases.
    Lee HL; Chung TS; Ting LL; Tsai JT; Chen SW; Chiou JF; Leung HW; Liu HE
    Radiat Oncol; 2012 Oct; 7():181. PubMed ID: 23110940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.
    Cai L; Zhu JF; Zhang XW; Lin SX; Su XD; Lin P; Chen K; Zhang LJ
    J Neurooncol; 2014 Nov; 120(2):423-30. PubMed ID: 25098700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.
    Balasubramanian SK; Sharma M; Venur VA; Schmitt P; Kotecha R; Chao ST; Suh JH; Angelov L; Mohammadi AM; Vogelbaum MA; Barnett GH; Jia X; Pennell NA; Ahluwalia MS
    Neuro Oncol; 2020 Feb; 22(2):267-277. PubMed ID: 31648302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
    J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
    Yu X; Sheng J; Pan G; Fan Y
    Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
    Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
    Saruwatari K; Ikeda T; Saeki S; Shingu N; Imamura K; Komatu T; Ushijima S; Maruyama H; Kashiwabara K; Tomita Y; Ichiyasu H; Fujii K; Sakagami T
    Anticancer Res; 2019 Feb; 39(2):923-931. PubMed ID: 30711977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal Growth Factor Receptor Mutation Status Confers Survival Benefit in Patients with Non-Small-Cell Lung Cancer Undergoing Surgical Resection of Brain Metastases: A Retrospective Cohort Study.
    Huang Y; Chow KKH; Aredo JV; Padda SK; Han SS; Kakusa BW; Hayden Gephart M
    World Neurosurg; 2019 May; 125():e487-e496. PubMed ID: 30710723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy.
    Sekine A; Satoh H; Iwasawa T; Tamura K; Hayashihara K; Saito T; Kato T; Arai M; Okudela K; Ohashi K; Ogura T
    Med Oncol; 2014 Oct; 31(10):228. PubMed ID: 25208818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score.
    Lee DW; Shin DY; Kim JW; Keam B; Kim TM; Kim HJ; Kim DW; Wu HG; Paek SH; Kim YW; Heo DS; Kim DG; Lee SH
    Lung Cancer; 2014 Dec; 86(3):363-8. PubMed ID: 25453849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
    Zhou S; Ren F; Meng X
    Front Immunol; 2022; 13():955944. PubMed ID: 36238280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of mutant p53, Ki-67, and TTF-1 and their correlation with EGFR mutation in patients with non-small cell lung cancer.
    Zhu WY; Hu XF; Fang KX; Kong QQ; Cui R; Li HF; He JY; Zhang YK; Le HB
    Histol Histopathol; 2019 Nov; 34(11):1269-1278. PubMed ID: 31062864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H
    BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel.
    Furuya N; Ito K; Sakaguchi T; Hida N; Kakinuma K; Morikawa K; Inoue T; Komase Y; Hataji O; Mineshita M
    Oncology; 2020; 98(9):661-668. PubMed ID: 32464632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases.
    Luo D; Ye X; Hu Z; Peng K; Song Y; Yin X; Zhu G; Ji Q; Peng Y
    Tumour Biol; 2014 Mar; 35(3):2437-44. PubMed ID: 24197981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.